Cell-cycle protein expression in a population-based study of ovarian and endometrial cancers

Ashley S. Felix, Mark E. Sherman, Stephen M. Hewitt, Munira Z. Gunja, Hannah P. Yang, Renata L. Cora, Vicky Boudreau, Kris Ylaya, Jolanta Lissowska, Louise A. Brinton, Nicolas Wentzensen

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Aberrant expression of cyclin-dependent kinase (CDK) inhibitors is implicated in the carcinogenesis of many cancers, including ovarian and endometrial cancers. We examined associations between CDK inhibitor expression, cancer risk factors, tumor characteristics, and survival outcomes among ovarian and endometrial cancer patients enrolled in a population-based case-control study. Expression (negative vs. positive) of three CDK inhibitors (p16, p21, and p27) and ki67 was examined with immunohistochemical staining of tissue microarrays. Logistic regression was used to estimate adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for associations between biomarkers, risk factors, and tumor characteristics. Survival outcomes were only available for ovarian cancer patients and examined using Kaplan-Meier plots and Cox proportional hazards regression. Among ovarian cancer patients (n = 175), positive p21 expression was associated with endometrioid tumors (OR = 12.22, 95% CI = 1.45-102.78) and higher overall survival (log-rank p = 0.002). In Cox models adjusted for stage, grade, and histology, the association between p21 expression and overall survival was borderline significant (hazard ratio = 0.65, 95% CI = 0.42-1.05). Among endometrial cancer patients (n = 289), positive p21 expression was inversely associated with age (OR = 65 years of age = 0.25, 95% CI = 0.07-0.84) and current smoking status (OR: 0.33, 95% CI 0.15, 0.72) compared to negative expression. Our study showed heterogeneity in expression of cell-cycle proteins associated with risk factors and tumor characteristics of gynecologic cancers. Future studies to assess these markers of etiological classification and behavior may be warranted.

Original languageEnglish (US)
Article number25
JournalFrontiers in Oncology
Volume5
Issue numberFEB
DOIs
StatePublished - 2015

Fingerprint

Cell Cycle Proteins
Endometrial Neoplasms
Ovarian Neoplasms
Confidence Intervals
Population
Odds Ratio
Neoplasms
Survival
Cyclin-Dependent Kinases
Cyclin-Dependent Kinase Inhibitor p16
Cyclin-Dependent Kinase Inhibitor p21
Cyclin-Dependent Kinase Inhibitor p27
Proportional Hazards Models
Case-Control Studies
Histology
Carcinogenesis
Biomarkers
Logistic Models
Smoking
Staining and Labeling

Keywords

  • Cell-cycle
  • Gynecologic cancer
  • Molecular etiology
  • Prognosis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Felix, A. S., Sherman, M. E., Hewitt, S. M., Gunja, M. Z., Yang, H. P., Cora, R. L., ... Wentzensen, N. (2015). Cell-cycle protein expression in a population-based study of ovarian and endometrial cancers. Frontiers in Oncology, 5(FEB), [25]. https://doi.org/10.3389/fonc.2015.00025

Cell-cycle protein expression in a population-based study of ovarian and endometrial cancers. / Felix, Ashley S.; Sherman, Mark E.; Hewitt, Stephen M.; Gunja, Munira Z.; Yang, Hannah P.; Cora, Renata L.; Boudreau, Vicky; Ylaya, Kris; Lissowska, Jolanta; Brinton, Louise A.; Wentzensen, Nicolas.

In: Frontiers in Oncology, Vol. 5, No. FEB, 25, 2015.

Research output: Contribution to journalArticle

Felix, AS, Sherman, ME, Hewitt, SM, Gunja, MZ, Yang, HP, Cora, RL, Boudreau, V, Ylaya, K, Lissowska, J, Brinton, LA & Wentzensen, N 2015, 'Cell-cycle protein expression in a population-based study of ovarian and endometrial cancers', Frontiers in Oncology, vol. 5, no. FEB, 25. https://doi.org/10.3389/fonc.2015.00025
Felix, Ashley S. ; Sherman, Mark E. ; Hewitt, Stephen M. ; Gunja, Munira Z. ; Yang, Hannah P. ; Cora, Renata L. ; Boudreau, Vicky ; Ylaya, Kris ; Lissowska, Jolanta ; Brinton, Louise A. ; Wentzensen, Nicolas. / Cell-cycle protein expression in a population-based study of ovarian and endometrial cancers. In: Frontiers in Oncology. 2015 ; Vol. 5, No. FEB.
@article{15ccf2d76312426aa0154ba031677b2b,
title = "Cell-cycle protein expression in a population-based study of ovarian and endometrial cancers",
abstract = "Aberrant expression of cyclin-dependent kinase (CDK) inhibitors is implicated in the carcinogenesis of many cancers, including ovarian and endometrial cancers. We examined associations between CDK inhibitor expression, cancer risk factors, tumor characteristics, and survival outcomes among ovarian and endometrial cancer patients enrolled in a population-based case-control study. Expression (negative vs. positive) of three CDK inhibitors (p16, p21, and p27) and ki67 was examined with immunohistochemical staining of tissue microarrays. Logistic regression was used to estimate adjusted odds ratios (ORs) and 95{\%} confidence intervals (CIs) for associations between biomarkers, risk factors, and tumor characteristics. Survival outcomes were only available for ovarian cancer patients and examined using Kaplan-Meier plots and Cox proportional hazards regression. Among ovarian cancer patients (n = 175), positive p21 expression was associated with endometrioid tumors (OR = 12.22, 95{\%} CI = 1.45-102.78) and higher overall survival (log-rank p = 0.002). In Cox models adjusted for stage, grade, and histology, the association between p21 expression and overall survival was borderline significant (hazard ratio = 0.65, 95{\%} CI = 0.42-1.05). Among endometrial cancer patients (n = 289), positive p21 expression was inversely associated with age (OR = 65 years of age = 0.25, 95{\%} CI = 0.07-0.84) and current smoking status (OR: 0.33, 95{\%} CI 0.15, 0.72) compared to negative expression. Our study showed heterogeneity in expression of cell-cycle proteins associated with risk factors and tumor characteristics of gynecologic cancers. Future studies to assess these markers of etiological classification and behavior may be warranted.",
keywords = "Cell-cycle, Gynecologic cancer, Molecular etiology, Prognosis",
author = "Felix, {Ashley S.} and Sherman, {Mark E.} and Hewitt, {Stephen M.} and Gunja, {Munira Z.} and Yang, {Hannah P.} and Cora, {Renata L.} and Vicky Boudreau and Kris Ylaya and Jolanta Lissowska and Brinton, {Louise A.} and Nicolas Wentzensen",
year = "2015",
doi = "10.3389/fonc.2015.00025",
language = "English (US)",
volume = "5",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",
number = "FEB",

}

TY - JOUR

T1 - Cell-cycle protein expression in a population-based study of ovarian and endometrial cancers

AU - Felix, Ashley S.

AU - Sherman, Mark E.

AU - Hewitt, Stephen M.

AU - Gunja, Munira Z.

AU - Yang, Hannah P.

AU - Cora, Renata L.

AU - Boudreau, Vicky

AU - Ylaya, Kris

AU - Lissowska, Jolanta

AU - Brinton, Louise A.

AU - Wentzensen, Nicolas

PY - 2015

Y1 - 2015

N2 - Aberrant expression of cyclin-dependent kinase (CDK) inhibitors is implicated in the carcinogenesis of many cancers, including ovarian and endometrial cancers. We examined associations between CDK inhibitor expression, cancer risk factors, tumor characteristics, and survival outcomes among ovarian and endometrial cancer patients enrolled in a population-based case-control study. Expression (negative vs. positive) of three CDK inhibitors (p16, p21, and p27) and ki67 was examined with immunohistochemical staining of tissue microarrays. Logistic regression was used to estimate adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for associations between biomarkers, risk factors, and tumor characteristics. Survival outcomes were only available for ovarian cancer patients and examined using Kaplan-Meier plots and Cox proportional hazards regression. Among ovarian cancer patients (n = 175), positive p21 expression was associated with endometrioid tumors (OR = 12.22, 95% CI = 1.45-102.78) and higher overall survival (log-rank p = 0.002). In Cox models adjusted for stage, grade, and histology, the association between p21 expression and overall survival was borderline significant (hazard ratio = 0.65, 95% CI = 0.42-1.05). Among endometrial cancer patients (n = 289), positive p21 expression was inversely associated with age (OR = 65 years of age = 0.25, 95% CI = 0.07-0.84) and current smoking status (OR: 0.33, 95% CI 0.15, 0.72) compared to negative expression. Our study showed heterogeneity in expression of cell-cycle proteins associated with risk factors and tumor characteristics of gynecologic cancers. Future studies to assess these markers of etiological classification and behavior may be warranted.

AB - Aberrant expression of cyclin-dependent kinase (CDK) inhibitors is implicated in the carcinogenesis of many cancers, including ovarian and endometrial cancers. We examined associations between CDK inhibitor expression, cancer risk factors, tumor characteristics, and survival outcomes among ovarian and endometrial cancer patients enrolled in a population-based case-control study. Expression (negative vs. positive) of three CDK inhibitors (p16, p21, and p27) and ki67 was examined with immunohistochemical staining of tissue microarrays. Logistic regression was used to estimate adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for associations between biomarkers, risk factors, and tumor characteristics. Survival outcomes were only available for ovarian cancer patients and examined using Kaplan-Meier plots and Cox proportional hazards regression. Among ovarian cancer patients (n = 175), positive p21 expression was associated with endometrioid tumors (OR = 12.22, 95% CI = 1.45-102.78) and higher overall survival (log-rank p = 0.002). In Cox models adjusted for stage, grade, and histology, the association between p21 expression and overall survival was borderline significant (hazard ratio = 0.65, 95% CI = 0.42-1.05). Among endometrial cancer patients (n = 289), positive p21 expression was inversely associated with age (OR = 65 years of age = 0.25, 95% CI = 0.07-0.84) and current smoking status (OR: 0.33, 95% CI 0.15, 0.72) compared to negative expression. Our study showed heterogeneity in expression of cell-cycle proteins associated with risk factors and tumor characteristics of gynecologic cancers. Future studies to assess these markers of etiological classification and behavior may be warranted.

KW - Cell-cycle

KW - Gynecologic cancer

KW - Molecular etiology

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84923629257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923629257&partnerID=8YFLogxK

U2 - 10.3389/fonc.2015.00025

DO - 10.3389/fonc.2015.00025

M3 - Article

VL - 5

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

IS - FEB

M1 - 25

ER -